Latest News about LOBEF
Recent news which mentions LOBEF
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
From Benzinga
From Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
June 28, 2023
Tickers
LOBEF
From Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
From Benzinga
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
April 20, 2023
Tickers
LOBEF
From Benzinga
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
February 28, 2023
Tickers
LOBEF
From Benzinga
Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials
October 14, 2022
Tickers
LOBEF
From Benzinga
Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
September 01, 2022
From Benzinga
This Psychedelic Company Just Signed An Exclusive Deal For Psilocin Clinical Trials In Australia
August 10, 2022
Tickers
LOBEF
From Benzinga
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
July 19, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.